Silver Gala Sponsor: UCB, a company that creates value for patients

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7500 people in approximately 40 countries, the company generated revenue of € 4.53 billion in 2017, and invested 23% of revenue into research and development. UCB is listed on Euronext Brussels (symbol: UCB).

Since UCB’s creation in 1928, innovation and agile entrepreneurship have been in the company’s DNA. Throughout its 90-year journey, UCB has continuously been pushing the boundaries and has never shied away from making bold moves to reinvent itself. This innovation spirit and agility mindset is still UCB’s signature today and will be for the future.

UCB started its initial pharmaceuticals business operations in China in the early 90s. In 1996, UCB opened its first representative office in Shanghai.  UCB leapfrogged to be a fast growing biopharma company in China with the acquisition of Schwarz Pharma and its Zhuhai plant in 2006 and the successful launch of Keppra® in the following year.

Head office locating in Shanghai, UCB China also has regional offices in Beijing, Chengdu, Guangzhou, and a manufacturing site in Zhuhai. With more than 750 employees in China, the company has positively impacted the lives of patients suffering from epilepsy, iron-deficiency anemia and recurrent respiratory tract infection. We are making great efforts to bring more innovative products and solutions in immunology and neurology to create value for more Chinese patients in the coming years.